Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

Carboplatin

Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression

DRUG

Bevacizumab

Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression

DRUG

Paclitaxel

Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression

Trial Locations (11)

Unknown

University General Hospital of Alexandroupolis, Alexandroupoli

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

"Marika Iliadis Hospital of Athens, Dep of Medical Oncology", Athens

"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

University Hospital of Crete, Heraklion

State General Hospital of Larissa, Dep of Medical Oncology, Larissa

"Diabalkaniko hospital, Thessaloniki", Thessaloniki

": Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER